Image source: Shutterstock

Highlights

  • Shares rise following AGM with discussion on market valuation concerns
  • Company highlights disconnect between analyst targets and current price
  • Nine analysts reportedly maintain buy ratings with significantly higher targets

Neuren Pharmaceuticals Ltd (ASX: NEU) shares have risen today to AUD 13.72, reflecting a 2% increase in response to investor sentiment following the company's recent annual general meeting (AGM). At the meeting, management acknowledged investor frustration regarding the company’s share price, which has fallen from its peak despite positive developments.

The company stated that all nine analysts covering Neuren maintain buy recommendations, with average target prices considerably above the current share price. This mismatch between analyst expectations and market valuation was described as disappointing by company leadership.

Neuren focuses on developing therapies for neurological conditions, and recent progress has included commercial and clinical milestones. Yet, despite these advancements, share performance has lagged. Management’s comments appear to be an attempt to align investor perception with the company’s view of its underlying value.

With the broader ASX market only slightly higher today, Neuren’s gains reflect a more targeted investor reaction to the company’s narrative. Continued performance will likely depend on commercial updates, pipeline progress, and future market communications.